{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:52:50Z","timestamp":1789645970974,"version":"4.0.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon","doi-asserted-by":"publisher","award":["GUP13013"],"award-info":[{"award-number":["GUP13013"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EuroBioBank"},{"name":"BBMRNR"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.bbadis.2014.06.031","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T20:15:58Z","timestamp":1404332158000},"page":"615-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Spectrum of metabolic myopathies"],"prefix":"10.1016","volume":"1852","author":[{"given":"Corrado","family":"Angelini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbadis.2014.06.031_bb0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archneur.1972.00490100074007","article-title":"Comparative study of acid maltase deficiency. Biochemical differences between infantile, childhood, and adult types","volume":"26","author":"Angelini","year":"1972","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"issue":"8","key":"10.1016\/j.bbadis.2014.06.031_bb0015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.55.8.1122","article-title":"Juvenile and adult-onset acid maltase deficiency in France: genotype\u2013phenotype correlation","volume":"55","author":"Lafor\u00eat","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bbadis.2014.06.031_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on Pompe disease in 42 German patients: molecular analysis of the GAA gene, manifestation and genotype\u2013phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.bbadis.2014.06.031_bb0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","article-title":"Course of disability and respiratory function in untreated late onset Pompe disease","volume":"66","author":"Hagemans","year":"2006","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.bbadis.2014.06.031_bb0035","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Group. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4years","volume":"259","author":"Angelini","year":"2012","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.bbadis.2014.06.031_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajmg.c.31322","article-title":"Toward deconstructing the phenotype of late-onset Pompe disease","volume":"160","author":"Sch\u00fcller","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0045","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","article-title":"Late-onset Pompe disease primarily affects quality of life in physical health domains","volume":"63","author":"Hagemans","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.031_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"Gungor","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.nmd.2011.11.003","article-title":"Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology","volume":"22","author":"Tsuburaya","year":"2012","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.bbadis.2014.06.031_bb0060","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.bbadis.2014.06.031_bb0065","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.bbadis.2014.06.031_bb0070","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/cdd.2012.52","article-title":"The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII)","volume":"19","author":"Nascimbeni","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid a-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"12","key":"10.1016\/j.bbadis.2014.06.031_bb0080","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.nmd.2010.09.011","article-title":"Where do we stand in enzyme replacement therapy in Pompe's disease?","volume":"20","author":"van der Ploeg","year":"2010","journal-title":"Neuromuscul. Disord."},{"issue":"19","key":"10.1016\/j.bbadis.2014.06.031_bb0085","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0b013e3182553c11","article-title":"Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy","volume":"78","author":"Ebbink","year":"2012","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.bbadis.2014.06.031_bb0090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"issue":"15","key":"10.1016\/j.bbadis.2014.06.031_bb0095","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbadis.2014.06.031_bb0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.bbadis.2014.06.031_bb0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.23340","article-title":"New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy","volume":"45","author":"Angelini","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.06.031_bb0110","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.nmd.2011.06.748","article-title":"Whole body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns","volume":"21","author":"Carlier","year":"2011","journal-title":"Neuromuscul. Disord."},{"issue":"4","key":"10.1016\/j.bbadis.2014.06.031_bb0115","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.06.031_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.c.31324","article-title":"The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management","volume":"160","author":"Kishnani","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.nmd.2011.04.001","article-title":"Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease","volume":"21","author":"Orlikowski","year":"2011","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.bbadis.2014.06.031_bb0135","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/mus.21943","article-title":"Phenotypical variability in glycogen storage disease type III with a recurrent AGL mutation c.750-753delAGAC","volume":"43","author":"Okubo","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bbadis.2014.06.031_bb0140","series-title":"GeneReviews\u2122","article-title":"Glycogen storage disease type III","author":"Dagli","year":"2010"},{"key":"10.1016\/j.bbadis.2014.06.031_bb0145","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/GIM.0b013e3181e655b6","article-title":"Glycogen storage disease type III diagnosis and management guidelines","volume":"12","author":"Kishnani","year":"2010","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.bbadis.2014.06.031_bb0150","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1203\/PDR.0b013e318232154f","article-title":"Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet","volume":"70","author":"Valayannopoulos","year":"2011","journal-title":"Pediatr. Res."},{"issue":"11","key":"10.1016\/j.bbadis.2014.06.031_bb0155","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/jnnp.2009.195040","article-title":"McArdle disease: a clinical review","volume":"81","author":"Quinlivan","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbadis.2014.06.031_bb0160","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2011-301593","article-title":"Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry","volume":"83","author":"Lucia","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2014.06.031_bb0165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0002-9343(83)90614-9","article-title":"Low muscle levels of pyridoxine in McArdle's syndrome","volume":"74","author":"Haller","year":"1983","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.bbadis.2014.06.031_bb0170","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/mus.22290","article-title":"Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy","volume":"45","author":"Sato","year":"2012","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.bbadis.2014.06.031_bb0175","first-page":"CD003458","article-title":"Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V)","volume":"8","author":"Quinlivan","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.bbadis.2014.06.031_bb0180","first-page":"CD007931","article-title":"Physical training for McArdle disease","volume":"7","author":"Quinlivan","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.bbadis.2014.06.031_bb0185","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archneur.65.6.786","article-title":"Effect of oral sucrose shortly before exercise on work capacity in McArdle disease","volume":"65","author":"Andersen","year":"2008","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.bbadis.2014.06.031_bb0190","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/adc.2008.146548","article-title":"Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity","volume":"79","author":"Andersen","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbadis.2014.06.031_bb0195","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/bjsports-2012-091130","article-title":"The \u2018McArdle paradox\u2019: exercise is a good advice for the exercise intolerant","volume":"47","author":"Lucia","year":"2013","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0200","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ana.10499","article-title":"Phenotype modulators in myophosphorylase deficiency","volume":"53","author":"Martinuzzi","year":"2003","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.bbadis.2014.06.031_bb0205","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/mus.20937","article-title":"Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease","volume":"37","author":"Martinuzzi","year":"2008","journal-title":"Muscle Nerve"},{"issue":"4076","key":"10.1016\/j.bbadis.2014.06.031_bb0210","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.179.4076.899","article-title":"Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome","volume":"179","author":"Engel","year":"1973","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbadis.2014.06.031_bb0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.25.1.16","article-title":"The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features","volume":"25","author":"Karpati","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2014.06.031_bb0220","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJM198012113032403","article-title":"Systemic carnitine deficiency \u2014 a treatable inherited lipid-storage disease presenting as Reye's syndrome","volume":"303","author":"Chapoy","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0225","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ng1951","article-title":"The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy","volume":"39","author":"Fischer","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0230","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbrc.2008.10.081","article-title":"Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy","volume":"377","author":"Campagna","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.bbadis.2014.06.031_bb0235","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00109-011-0725-7","article-title":"Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoAdehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A","volume":"89","author":"Wang","year":"2011","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.bbadis.2014.06.031_bb0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11910-010-0154-y","article-title":"Lipid storage myopathy","volume":"11","author":"Liang","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"15","key":"10.1016\/j.bbadis.2014.06.031_bb0245","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/hmg\/dds175","article-title":"Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency","volume":"21","author":"Cornelius","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.bbadis.2014.06.031_bb0250","first-page":"351","article-title":"State of the art in muscle lipid diseases","volume":"29","author":"Liang","year":"2010","journal-title":"Acta Myol."},{"issue":"3","key":"10.1016\/j.bbadis.2014.06.031_bb0255","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-0004.2011.01786.x","article-title":"Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency","volume":"82","author":"Fanin","year":"2012","journal-title":"Clin. Genet."},{"issue":"4","key":"10.1016\/j.bbadis.2014.06.031_bb0260","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.WNL.0000078195.05396.20","article-title":"Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency","volume":"61","author":"\u00d8rngreen","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.bbadis.2014.06.031_bb0265","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1212\/WNL.59.7.1046","article-title":"Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose","volume":"59","author":"\u00d8rngreen","year":"2002","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.bbadis.2014.06.031_bb0270","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1056\/NEJMc0806334","article-title":"Bezafibrate for an inborn mitochondrial beta-oxidation defect","volume":"360","author":"Bonnefont","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbadis.2014.06.031_bb0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/clpt.2010.55","article-title":"Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency","volume":"88","author":"Bonnefont","year":"2010","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443914002087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443914002087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T19:26:38Z","timestamp":1538421998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443914002087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0925443914002087"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2014.06.031","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spectrum of metabolic myopathies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2014.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}